Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14311936 | 0.98 | KMT2A (0.35) | KMT2AGAARAD52NCF1SLC6A2 | |
| Hydrochloric Acid SCHEMBL7401430 | 0.98 | KMT2A (0.35) | KMT2AGAARAD52NCF1SLC6A2 | |
| Hydrochloric Acid SCHEMBL9030273 | 0.95 | NPSR1 (0.34) | KMT2AGAARAD52NCF1SLC6A2 | |
| SCHEMBL20007916 | 0.91 | KMT2A (0.33) | KMT2AGAARAD52NCF1SLC6A2 | |
| Acetic Acid SCHEMBL10639731 | 0.91 | CYP1A2 (0.37) | KMT2AGAARAD52SLC6A2SLC6A4 | |
| SCHEMBL16295697 | 0.86 | — | — | |
| SCHEMBL8589603 | 0.82 | NPSR1 (0.36) | SLC6A2SLC6A3CYP1A2NPSR1MAPK1 | |
| SCHEMBL383477 | 0.81 | NCF1 (0.33) | KMT2AGAARAD52NCF1CYP1A2 | |
| SCHEMBL8372902 | 0.77 | KMT2A (0.34) | KMT2AGAASLC6A4NPSR1MAPK1 | |
| SCHEMBL3436780 | 0.77 | NPSR1 (0.33) | KMT2AGAANPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-114507184-A | Synthesis method and application of 1-methylhexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114507184-B | Synthesis method and application of 1-methyl hexahydroazepin-4-one hydrochloride | 好医生药业集团有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-111936496-B | Heterocyclic compounds useful as medicaments | 马萨里克大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-1129942-A | Aza spiro-compounds acting on the cholinergic system with muscarinic agonist activity | ISRAEL INST BIOLOG RES (IL) | 1996-08-28 | — | — | CN | disclosed |
| US-5534520-A | Spiro compounds containing five-membered rings | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1996-07-09 | — | — | US | disclosed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5407938-A | Treating central nervous system disorders; Alzheimer*s | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-04-18 | — | — | US | disclosed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | disclosed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | disclosed |
| EP-0343307-A1 | 4-Piperidinealkanamine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1989-11-29 | — | — | EP | disclosed |
| EP-0295833-A1 | Aromatic-Spiropiperidine oxazepinones (and thiones) | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4746655-A | ANTIHISTAMINES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | KMT2A 1046/4885GAA 4532/4885RAD52 3023/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | KMT2A 2962/4885GAA 3665/4885RAD52 3678/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | KMT2A 1046/4885GAA 4532/4885RAD52 3023/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | KMT2A 186/4885GAA 3730/4885RAD52 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.